Literature DB >> 17321328

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.

Mercedes Marín-Aguilera1, Lourdes Mengual, María José Ribal, Moisès Burset, Yolanda Arce, Elisabet Ars, Artur Oliver, Humberto Villavicencio, Ferran Algaba, Antonio Alcaraz.   

Abstract

We evaluated the performance of a multiprobe FISH (fluorescence in situ hybridization) assay for noninvasive detection of superficial urothelial carcinoma (UC) in the bladder, in comparison to urinary cytology. Voided urine samples from 74 patients with superficial UC were analyzed by both techniques. Urine samples from 19 patients with muscle-invasive tumors and from 19 healthy control subjects were also studied. For FISH analysis, labeled probes for chromosomes 3, 7, 9, and 17 were used to assess chromosomal abnormalities indicative of malignancy. We found a significant difference between the overall sensitivity of FISH and cytology in superficial UC detection (70.3 versus 35.1%, respectively; P < 0.0001). This significant difference was maintained when superficial UCs were broken down into low grade (52.8 versus 13.9%, respectively; P < 0.0005) and high grade (86.8 versus 55.3%, respectively; P < 0.0015) tumors. Overall specificity was 100% for cytology and 94.7% for FISH (difference not significant). Of patients with suspicious cytology, 69% were positive by FISH. Together, these findings suggest that FISH assay for chromosomes 3, 7, 9, and 17 has a higher sensitivity than cytology and a similar specificity in the detection of superficial UC--which could be useful for reducing some cystoscopies in the accurate follow-up usually performed in these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17321328     DOI: 10.1016/j.cancergencyto.2006.10.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers.

Authors:  Torsten Gruschwitz; Mieczyslaw Gajda; Astrid Enkelmann; Marc-Oliver Grimm; Heiko Wunderlich; Marcus Horstmann; Kerstin Junker
Journal:  Int Urol Nephrol       Date:  2014-04-22       Impact factor: 2.370

2.  Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma.

Authors:  Tianhai Lin; Zhenhua Liu; Liangren Liu; Lu Yang; Ping Han; Peng Zhang; Qiang Wei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

3.  Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study.

Authors:  Nancy P Caraway; Abha Khanna; Ricardo L Fernandez; Linda Payne; Roland L Bassett; Hua-Zhong Zhang; Ashish Kamat; Ruth L Katz
Journal:  Cancer Cytopathol       Date:  2010-10-25       Impact factor: 5.284

Review 4.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

5.  Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand.

Authors:  Xing-You Jia; Qi Yu; Zhe-Hui Zhang; Xiao-Feng Yang
Journal:  Onco Targets Ther       Date:  2012-05-07       Impact factor: 4.147

6.  The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.

Authors:  Kyung Won Kwak; Sun Hee Kim; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

7.  UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study.

Authors:  Yavuz Dodurga; Cığır Biray Avcı; Sunde Yılmaz; Oktay Nazlı; Ozgür Coğulu; Tufan Cankaya; Cumhur Gündüz
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.